Pfizer discontinues support of CME

Pfizer will no longer fund continuing medical education through med ed firms. 

The company, that was until recently the leading supporter of CME, said it will continue to support CME programs provided by academic medical centers and teaching hospitals, associations, medical societies and community hospitals, but will no longer offer direct funding for programs provided by MECCs.

The move is aimed at tempering concerns that industry support biases CME content. 

“We understand that even the appearance of conflicts in CME is damaging and we are determined to take actions that are in the best interests of patients and physicians,” said Pfizer chief medical officer Dr. Joseph Feczko in a statement.

Pfizer's support of CME has dropped considerably in recent years. In 2005, the company spent $314 million on all forms of CME, according to Verispan figures. In 2006, CME support dropped to $285 million, again according to Verispan. 

Last year, the Pfizer reported spending around $80 million on CME. In May, as part of a transparency push, Pfizer posted a list of $10 million in med ed grants for the first quarter of 2008. 

The company acknowledged that some supported med ed programs will be contracted out to MECCs by academic and institutional providers. 

Tom Sullivan, president of med ed firm Rockpointe, questioned whether funding academic and institutional providers, which will contract commercial providers to execute many programs, increases transparency: “How does having multiple provider situations make it really transparent?”

In a statement, the Coalition for Healthcare Communication said: “Senior CME professionals throughout the industry agree that commercial education companies are among the finest in the industry. However, many uninformed public policy makers and other critics of the industry have unfairly singled out commercial providers, leading Pfizer to the unfortunate decision.” 
You must be a registered member of MMM to post a comment.

Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.